On 27 October 2025 in Hanoi, the inaugural China Pharmaceutical Equipment Industry Association (CPEIA) – Vietnam MilitaryCivil Medical Association (VMCMA) China-Vietnam Pharmaceutical Equipment Promotion Conference took place, gathering industry leaders from both countries. On the Chinese side, CPEIA Chairman Mr. Tang Yue, Vice-Chairmen Mr. He Zhizhen, Mr. Wang Huyu and Mr. Yang Song, and Secretary-General Ms. Wang Yajun attended; from the Vietnamese side, Executive Vice-Chairman Dr. Chu Tiến Cường represented VMCMA. The session was chaired by Mr. Yang Song, who also facilitated the programme. Mr. He Zhizhen delivered a presentation on the Chinese pharmaceutical-equipment sector’s progress. The conference concluded with Mr. Tang Yue and Dr. Chu Tiến Cường signing a China-Vietnam cooperation agreement.

China and Vietnam’s bilateral trade and industrial-chain cooperation have been developing steadily: China remains Vietnam’s largest trade partner and key supplier of goods and raw materials. During a state visit in April 2025, the two governments committed to fully leveraging bilateral mechanisms to promote cooperation in trade, investment and technology transfer. This promotion conference is a concrete manifestation of that trust- and cooperation-based relationship.

The VMCMA, approved under Vietnam’s Interior Ministry and headquartered within the Ministry of Health, currently comprises ten foundational branches and eleven research institutes. It conducts numerous applied-R&D projects in traditional medicine, stem-cell technologies and public-health innovation, and convenes influential domestic and international scientific symposia, with a membership numbering in the tens of thousands across military and civilian medical sectors. The association is committed to advancing public-health planning, expanding its professional network, and promoting international industry exchange. (Information supplied by VMCMA.)

Chinese equipment firms attending the conference brought a comprehensive product range spanning liquid-dose equipment, solid-dose equipment, TCM (traditional Chinese medicine) equipment, API (active-pharmaceutical-ingredient) equipment and packaging systems. Dozens of key Vietnamese pharmaceutical enterprises participated, with product coverage across chemical pharmaceuticals, APIs and TCM. Mr. Tang Yue remarked:

“Many of you are long-standing friends of Chinese pharmaceutical equipment. We are assisting your enterprise upgrade-development. We have focussed on Vietnamese demand and brought full-process equipment and solutions that meet international standards while adapting to local requirements, to support Vietnam’s health-industry development.”

Dr. Chu Tiến Cường, in his address, extended a warm welcome to the Chinese delegation and reaffirmed:

“This event carries significant meaning—it fully reflects the neighbourly friendship and cooperative spirit between Vietnam and China.”

He added that Vietnam’s pharmaceutical sector has made leaps forward and is progressively integrating into global value-chains. These achievements owe much to Chinese firms’ contributions in equipment, technology and advanced-solution transfer. He further emphasised that international cooperation remains a key pillar and the VMCMA highly values Chinese partners’ support in providing equipment, technology and sharing experience in drug-R&D and production.

Vietnam’s pharma market has shown strong development potential in recent years, with growth entering double digits and the market size projected to reach USD 10 billion by 2026. The Vietnamese government is actively driving pharma enterprises toward “digitisation, intelligent manufacturing and green transformation”. The demand for upgrading Chinese-medicine, chemical-medicine and API production equipment is pressing; the demand for efficient, compliant, intelligent pharmaceutical equipment is rising accordingly. On the Chinese side, the pharmaceutical-equipment industry has continued scaling up its technology, capability and comprehensive strength—particularly in intelligent, green and high-end equipment domains—represented by firms such as Truking Technology Co., Ltd. (TRUKING). These firms offer rich product lines capable of servicing full-process production needs in both domestic and export markets.

In the signed agreement, Mr. Tang Yue and Dr. Chu Tiến Cường committed to deepen cooperation. China will adopt a more open posture, listen to Vietnam’s market needs, continuously optimise equipment performance and service systems, and help Vietnamese partners reduce cost, increase efficiency and enhance core competitiveness. They also laid the groundwork for future collaboration in human-resource training, drug R&D, and application of high-tech equipment in disease diagnosis and treatment. Dr. Chu Tiến Cường emphasised:

“With belief in friendship, intelligence and technological power, I am confident our cooperation will open new doors—bringing science, humanitarianism and a cooperative spirit together, to make greater contributions to people’s health.”

China’s pharmaceutical industry already ranks among the world’s advanced in both technology and scale, and Vietnam’s pharmaceutical industry is now in a high-growth window. The cooperation opportunities across technology, production capacity and equipment are broad. Mr. Tang Yue stated:

“We are now in the best historical period for China–Vietnam pharmaceutical-industry development and cooperation. This context not only gave birth to the cooperation of our two professional associations, but will also drive further China–Vietnam collaboration in drug-production technology and equipment. We are very willing to do more practical facilitation work for China–Vietnam industry cooperation and development, and to make greater contributions to Vietnam’s pharma-industry development and the health of the Vietnam people.”